ICML 2023 | The evolving role of MRD in DLBCL
Umberto Vitolo, MD, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, comments on the role of measurable residual disease (MRD) in refining prognosis in diffuse large B-cell lymphoma (DLBCL). Prof. Vitolo explains the benefits of using circulating tumor DNA (ctDNA) to detect and measure MRD and combining this with PET results to gain more information about patient responses to treatment. Prof. Vitolo also highlights the use of MRD assessment in the POLARIX trial (NCT03274492), before noting the need for harmonization of detection technologies across clinical studies. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
